| Literature DB >> 29625040 |
Lucile Pantel1, Tanja Florin2, Malgorzata Dobosz-Bartoszek3, Emilie Racine1, Matthieu Sarciaux1, Marine Serri1, Jessica Houard1, Jean-Marc Campagne4, Renata Marcia de Figueiredo4, Camille Midrier4, Sophie Gaudriault5, Alain Givaudan5, Anne Lanois5, Steve Forst6, André Aumelas1, Christelle Cotteaux-Lautard7, Jean-Michel Bolla7, Carina Vingsbo Lundberg8, Douglas L Huseby9, Diarmaid Hughes9, Philippe Villain-Guillot1, Alexander S Mankin10, Yury S Polikanov11, Maxime Gualtieri12.
Abstract
Growing resistance of pathogenic bacteria and shortage of antibiotic discovery platforms challenge the use of antibiotics in the clinic. This threat calls for exploration of unconventional sources of antibiotics and identification of inhibitors able to eradicate resistant bacteria. Here we describe a different class of antibiotics, odilorhabdins (ODLs), produced by the enzymes of the non-ribosomal peptide synthetase gene cluster of the nematode-symbiotic bacterium Xenorhabdus nematophila. ODLs show activity against Gram-positive and Gram-negative pathogens, including carbapenem-resistant Enterobacteriaceae, and can eradicate infections in animal models. We demonstrate that the bactericidal ODLs interfere with protein synthesis. Genetic and structural analyses reveal that ODLs bind to the small ribosomal subunit at a site not exploited by current antibiotics. ODLs induce miscoding and promote hungry codon readthrough, amino acid misincorporation, and premature stop codon bypass. We propose that ODLs' miscoding activity reflects their ability to increase the affinity of non-cognate aminoacyl-tRNAs to the ribosome.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29625040 DOI: 10.1016/j.molcel.2018.03.001
Source DB: PubMed Journal: Mol Cell ISSN: 1097-2765 Impact factor: 17.970